Trending NewsTrending NewsTop MarketRank™ StocksTop MarketRank™NYSE:CHE Chemed (CHE) Stock Price, News & Analysis $416.31 -48.38 (-10.41%) Closing price 07/30/2025 03:59 PM EasternExtended Trading$445.10 +28.80 (+6.92%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Chemed Stock (NYSE:CHE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Chemed alerts:Sign Up Key Stats Today's Range$410.00▼$433.8150-Day Range$450.09▼$579.5352-Week Range$410.00▼$623.60Volume521,967 shsAverage Volume137,280 shsMarket Capitalization$6.09 billionP/E Ratio21.40Dividend Yield0.48%Price Target$596.67Consensus RatingModerate Buy Company Overview Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio. Read More Chemed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks100th Percentile Overall ScoreCHE MarketRank™: Chemed scored higher than 100% of companies evaluated by MarketBeat, and ranked 9th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingChemed has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageChemed has only been the subject of 3 research reports in the past 90 days.Read more about Chemed's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.73% Earnings GrowthEarnings for Chemed are expected to grow by 8.73% in the coming year, from $21.43 to $23.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemed is 21.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemed is 21.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.20.Price to Earnings Growth RatioChemed has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioChemed has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.01% of the float of Chemed has been sold short.Short Interest Ratio / Days to CoverChemed has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemed has recently decreased by 14.83%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldChemed has a dividend yield of 0.43%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthChemed has been increasing its dividend for 16 years.Dividend CoverageThe dividend payout ratio of Chemed is 9.74%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chemed will have a dividend payout ratio of 8.58% next year. This indicates that Chemed will be able to sustain or increase its dividend.Read more about Chemed's dividend. Sustainability and ESG4.9 / 5Environmental Score-0.33 Percentage of Shares Shorted3.01% of the float of Chemed has been sold short.Short Interest Ratio / Days to CoverChemed has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemed has recently decreased by 14.83%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.53 News SentimentChemed has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Chemed this week, compared to 10 articles on an average week.Search Interest6 people have searched for CHE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Chemed to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Chemed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,598,450.00 in company stock.Percentage Held by InsidersOnly 3.29% of the stock of Chemed is held by insiders.Percentage Held by Institutions95.85% of the stock of Chemed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemed's insider trading history. Receive CHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter. Email Address CHE Stock News HeadlinesChemed Corporation (CHE) Q2 2025 Earnings Call TranscriptJuly 30 at 7:58 PM | seekingalpha.comWhy Chemed Stock Is Plummeting TodayJuly 30 at 7:58 PM | msn.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. | Paradigm Press (Ad)Chemed revises 2025 EPS guidance to $22–$22.30, signals no significant 2026 Medicare cap in FloridaJuly 30 at 7:58 PM | msn.comVITAS® Healthcare Announces CEO Transition and Appointment of New Chief Executive OfficerJuly 30 at 4:22 PM | globenewswire.comWhy Chemed (CHE) Stock Is Trading Lower TodayJuly 30 at 2:57 PM | msn.comChemed shares tumble as Q2 earnings fall short, guidance disappointsJuly 30 at 9:56 AM | au.investing.comChemed Shares Fall On Earnings Miss, Executive DepartureJuly 30 at 9:56 AM | marketwatch.comSee More Headlines CHE Stock Analysis - Frequently Asked Questions How have CHE shares performed this year? Chemed's stock was trading at $529.80 at the beginning of 2025. Since then, CHE shares have decreased by 21.4% and is now trading at $416.31. How were Chemed's earnings last quarter? Chemed Corporation (NYSE:CHE) posted its quarterly earnings data on Tuesday, July, 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by $1.75. Chemed's revenue for the quarter was up 3.8% on a year-over-year basis. Read the conference call transcript. Who are Chemed's major shareholders? Chemed's top institutional shareholders include William Blair Investment Management LLC (2.32%), Boston Trust Walden Corp (1.69%), TD Asset Management Inc (1.68%) and DekaBank Deutsche Girozentrale (1.06%). Insiders that own company stock include Kevin J Mcnamara, Spencer S Lee, David Patrick Williams, Nicholas Michael Westfall, Andrea R Lindell, Patrick P Grace, George J Walsh III, Michael D Witzeman and Brian C Judkins. View institutional ownership trends. How do I buy shares of Chemed? Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemed investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Record date for 6/17 Dividend5/29/2025Ex-Dividend for 6/17 Dividend5/29/2025Dividend Payable6/17/2025Last Earnings7/29/2025Today7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealth Care Services Current SymbolNYSE:CHE CIK19584 Webwww.chemed.com Phone(513) 762-6690Fax513-762-6590Employees15,695Year Founded1970Price Target and Rating Average Price Target for Chemed$596.67 High Price Target$650.00 Low Price Target$500.00 Potential Upside/Downside+43.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$20.53 Trailing P/E Ratio20.28 Forward P/E Ratio19.43 P/E Growth2.26Net Income$302 million Net Margins12.40% Pretax Margin16.50% Return on Equity27.58% Return on Assets18.96% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.70 Sales & Book Value Annual Sales$2.49 billion Price / Sales2.45 Cash Flow$22.96 per share Price / Cash Flow18.13 Book Value$74.35 per share Price / Book5.60Miscellaneous Outstanding Shares14,629,000Free Float14,148,000Market Cap$6.09 billion OptionableOptionable Beta0.50 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:CHE) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.